UNIMED, TN0007720014

UNIMED seeks two directors and analyst targets UNIMED stock at TND 10.60

Published on 10/14/2026 at 03:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UNIMED opened two board seats on September 22, 2026. One analyst rates UNIMED stock Sell as 2025 profit fell 3.98 percent to TND 18.60 million.

Board search and analyst view

UNIMED opened two independent director positions for its 2026 to 2028 board term on September 22, 2026.
A 12-month analyst target of TND 10.60 carries a stated 21.14 percent upside.
Fiscal 2025 net income fell 3.98 percent to TND 18.60 million.

UNIMED, TN0007720014, Illustration mit AI erstellt.

UNIMED (ISIN TN0007720014) opened a search for two independent directors on September 22, 2026, while one analyst set a 12-month target of TND 10.60 for UNIMED stock. Managers reported that the appointments would cover the 2026, 2027 and 2028 fiscal years, subject to approval at the next annual meeting. Investing.com shows one analyst rating the stock Sell and a TND 10.60 average target with a stated 21.14 percent upside.

Board search follows annual meeting

The governance timetable began with Unimed's ordinary annual meeting on June 17, 2026. TSI published the post-meeting resolutions, the balance sheet after the allocation of earnings and the list of board members on September 21, 2026.

The following day's notice sought candidates with at least 10 years of experience in industry, finance or insurance. Applications were due by October 1, 2026 at 5:00 p.m., after which the nomination committee was to submit its selected names to Tunisia's financial regulator.

What does the target imply?

The TND 10.60 target is paired with a Sell consensus rather than a Buy recommendation, making the numerical target and the stated rating point in different directions. For investors, that split matters more than the target alone because the source records just one analyst view.

UNIMED's reported fiscal 2025 revenue was TND 148.91 million, while net income was TND 18.60 million, down 3.98 percent year over year. The same statement lists EBITDA at TND 42.94 million and operating cash flow at TND 22.52 million for fiscal 2025. Investing.com identifies all figures as millions of TND except per-share data.

Pharmaceutical platform remains central

UNIMED describes itself as a Tunisian pharmaceutical manufacturer established in 1989, with products including eye drops, liquid injectables, powder injectables and infusion solutions. Its website also highlights a partnership with G CUBE to manufacture rapid tests for Africa, giving the board search a governance angle alongside the company's manufacturing operations.

Historical price context

The last quoted value shown for UNIMED was TND 8.77 on October 9, 2026, with a 52-week range of TND 7.90 to TND 11.00. The range places the quoted value below the upper end of the year's trading band, while the analyst target remains a separate valuation reference in TND.

Market context: Latest market reports.